Fig 8 - by Junhui Kim (18575083)

Subjects:

The authorship rating was a 6-point rating scale of the degree of authorship, ranging from 1 “I could not manipulate the window at all” to 6 “I completely manipulated the window”.... by Junhui Kim (18575083)

Subjects:

Fig 1 - by Junhui Kim (18575083)

Subjects:

Estimated covariance parameter and fixed coefficients for the authorship questionnaire, comparing the “other” to the “delay” response. by Junhui Kim (18575083)

Subjects:

Relative saccade amplitude distribution. by Junhui Kim (18575083)

Subjects:

The proportion of participants who reported authorship (self, delay, or other). by Junhui Kim (18575083)

Subjects:

Testicular involution prior to sex change in gilthead seabream is characterized by a decrease in DMRT1 gene expression and by massive leukocyte infiltration-3 by Sergio Liarte (75701)

“…<p><b>Copyright information:</b></p><p>Taken from "Testicular involution prior to sex change in gilthead seabream is characterized by a decrease in DMRT1 gene expression and by massive leukocyte infiltration"</p><p>http://www.rbej.com/content/5/1/20</p><p>Reproductive Biology and Endocrinology 2007;5():20-20.…”

Fig 2 - by Jung-Kwon Bae (11432672)

Table_5_α-Ketoglutarate stimulates cell growth through the improvement of glucose and glutamine metabolism in C2C12 cell culture.DOCX by Bingquan Yang (6389006)

“…</p>Results<p>The control cells showed a CFE at 50%, a typical cell growth curve in the first 5 days with a mean SGR at 0.86/day, and a mean cell count doubling time at 19.4 h. …”

nFOXP3/cFOXP3 ratio is a reliable indicator of tumor recurrence in OSCC. by Donald T. Weed (448342)

“…<p>A) The percentage of CD4⁺cFOXP3⁺cells was plotted against the percentage of nFOXP3⁺cells in tumor free (white circle) or recurrent (red circle) patients. …”

Key safety measures including adverse events. by Anuja Dokras (8679261)

“…A total of 169 participants (70.4%) completed the trial between January 2018 and June 2023 (mean age: 29.5 years; mean BMI: 35.6 kg/m²; 70% were White and 23% were Black). …”

Averaged first slice of second-order kernel of the mfERGs of the nasal hemisphere within the central 7.5° for different stages of glaucoma (Blue trace: Advanced stage, Brown trace:... by Naoya Moroto (14419705)

Boxplots showing the differences in miR-21-5p and miR-16-5p levels across increasing AKI severity based on Kidney Disease: Improving Global Outcomes (KDIGO) grades. by Tamar J. van der Aart (22184206)

The boxplots present the mean cross-validated integrated Brier scores from the 1000 simulations for each of the sample sizes for the interaction simulations. by Justine B. Nasejje (14307679)

Proliferation rates of Vasa2+/Piwi1+ were independent on the daytime of the sampling, and mitotic rates were not significantly different upon refeeding of 5- or 20-day-starved poly... by Eudald Pascual-Carreras (12115380)

Brain uptake rate of [¹⁴C]docosahexaenoic acid (DHA) in the whole brain and each brain region. by Takuro Iwao (14636741)

Brain uptake rate of [¹⁴C]sucrose in the whole brain and individual brain regions. by Takuro Iwao (14636741)

Image2_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIF by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

Image1_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIFF by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

Image3_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIF by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”